Abstracts Archive - Page 596 of 2425 - ACR Meeting Abstracts

Abstract Number: 0658 • ACR Convergence 2021
ACCORD: A Novel Rheumatology Transition Clinic Structure for Adolescent and Young Adult Patients with Childhood Onset Rheumatic Disease
Rebecca Overbury¹, Kelly Huynh², Tracy Frech¹, John Bohnsack¹ and Aimee Hersh¹, ¹University of Utah, Salt Lake City, UT, ²Intermountain Health Care, Salt Lake City, UT
Background/Purpose: The transition of health care from Pediatric to Adult providers for adolescents and young adults with childhood onset rheumatic disease continues to be associated…
Abstract Number: 0657 • ACR Convergence 2021
Assessing Patient Transition Outcomes from a Large Pediatric Rheumatology Center to Adult Healthcare
Mary Robichaux¹, Bernard Danna², Monique Maher², David McDonald¹, Kristiana Nasto¹, Alexander Alexander¹, Ariel Coleman³, Danielle Guffey¹ and Tiphanie Vogel¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Texas Children's Hospital, Houston, TX
Background/Purpose: Transitioning children with chronic diseases from pediatric to adult healthcare can be a challenging task, with high morbidity and mortality. In response, we have…
Abstract Number: 0652 • ACR Convergence 2021
Application of a GCA Probability Score to Patients Referred to a GCA Fast Track Clinic
Mmoloki Mathake¹, Julia Murdoch², Andrew Taylor³, Jean-Louis deSousa², Kathy Jao², Rachel Li² and Helen Keen⁴, ¹Fiona Stanley Hospital, Beckenham, Australia, ²Royal Perth Hospital, Perth, Australia, ³Fiona Stanley Hospital, Murdoch, Australia, ⁴Fiona Stanley Hospital, Perth, Australia
Background/Purpose: Giant cell arteritis (GCA) is the most common large vessel vasculitis, and may be associated with irreversible blindness(1). It is therefore essential to make…
Abstract Number: 0663 • ACR Convergence 2021
Disappearing Digits: A National Retrospective Matched Cohort Study Examining the Risk of Lower Extremity Amputation in Gout
Quint Soto¹, Alison Petro¹, Bryant England¹, Harlan Sayles¹, Lindsay Helget¹, Punyasha Roul¹, Tuhina Neogi², James O'Dell¹, Brian LaMoreaux³ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA, ³Horizon Therapeutics plc, Deerfield, IL
Background/Purpose: Gout is associated with a number of comorbidities such as diabetes that are known risk factors for peripheral vascular disease. These comorbidities along with…
Abstract Number: 0662 • ACR Convergence 2021
Serum Urate Reduction Is Causally Associated with Flare Outcomes in People with Gout: Evidence for Surrogate Status from a Pooled Analysis of 2 Randomized Trials
Lisa Stamp¹, Chris Frampton¹, Melanie Morillon², William Taylor³, Nicola Dalbeth⁴, Jasvinder Singh⁵, Micheal Doherty⁶, Weiya Zhang⁶, Helen Richardson⁶, Aliya Sarmanova⁷ and Robin Christensen⁸, ¹University of Otago, Christchurch, Christchurch, New Zealand, ²Odense University Hospital, Odense, Denmark, ³University of Otago, Wellington, New Zealand, ⁴University of Auckland, Auckland, New Zealand, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Nottingham, Nottingham, United Kingdom, ⁷University of Bristol Medical School, Bristol, United Kingdom, ⁸Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark
Background/Purpose: Use of serum urate (SU) as a treatment target and outcome measure has become controversial in light of the American College of Physician Gout…
Abstract Number: 0660 • ACR Convergence 2021
Improving the Gout Flare Chart Review Using Linked Claims-EHR Data
Kazuki Yoshida, Tianrun Cai, Lily G. Bessette, Erin Kim, Su Been Lee, Luke E. Zabotka, Alec Sun, Jun Liu, DH Solomon, Katherine Liao and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Recurrent gout flares are the most crucial outcome in studies of gout treatment. However, gout flares is challenging to identify in a large population…
Abstract Number: 0664 • ACR Convergence 2021
Which Attributes Are the Most and Least Important to Patients When Considering Gout Flare Burden over Time? A Best-worst Scaling Choice Study
Jeremy Holyer¹, William Taylor², Angelo Gaffo³, Graham Hosie¹, Anne Horne¹, Borislav Mihov¹, Isabel Su¹, Gregory Gamble¹, Nicola Dalbeth¹ and Sarah Stewart¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago Wellington, Auckland, New Zealand, ³University of Alabama at Birmingham Medical Centre, Birmingham, AL
Background/Purpose: Several factors contribute to the patient experience of gout flares, including pain intensity, duration, frequency, and disability. It is unknown which of these factors…
Abstract Number: 0666 • ACR Convergence 2021
Process Mapping Gout Hospitalizations: A Deep Dive into an Avoidable Epidemic
Mark Russell¹, Benjamin Ellis², Benjamin Clarke¹, Deepak Nagra¹ and James Galloway³, ¹King's College London, London, United Kingdom, ²Imperial College Healthcare NHS Trust, London, United Kingdom, ³Kings College London, London, United Kingdom
Background/Purpose: Hospital admissions for gout flares have increased dramatically in recent years. Strategies to reduce hospitalizations and improve uptake of urate-lowering therapy (ULT) are needed.…
Abstract Number: 0665 • ACR Convergence 2021
Pegloticase Treatment for Uncontrolled Gout in Kidney Transplanted Patients: Results of an On-going Multicenter, Open-Label, Efficacy and Safety Study
Abdul Abdellatif¹, Lin Zhao², Paul M. Peloso³, Katya Cherny², Brad Marder², John D. Scandling⁴ and Kenneth Saag⁵, ¹Kidney Hypertension Transplant Clinic Clear Lake Specialties, Webster, TX, ²Horizon Therapeutics plc, Deerfield, IL, ³Horizon Therapeutics plc, Gurnee, IL, ⁴Stanford Medicine, Department of Nephrology, Stanford, CA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout in kidney transplant (KT) recipients can be severe and particularly challenging to manage. Pegloticase (pegylated recombinant uricase) rapidly metabolizes urate and is a…
Abstract Number: 0661 • ACR Convergence 2021
Effect of Omega-three Supplementation on Serum Urate and Gout Flares in People with Gout; A Pilot Randomized Trial
Lisa Stamp¹, Rebecca Grainger², Chris Frampton¹, Jill Drake¹ and Catherine Hill³, ¹University of Otago, Christchurch, Christchurch, New Zealand, ²University of Otago, Wellington, New Zealand, ³Queen Elizabeth Hospital, Woodville, Australia
Background/Purpose: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), also known as omega-3 fats act as alternate COX substrates to arachidonic acid (AA). Their metabolism results…
Abstract Number: 0655 • ACR Convergence 2021
Depression and Fatigue: Two Forgotten Associated Comorbidities in Patients with Rheumatoid Arthritis
Rosa Morlà¹, Beatriz Frade-Sosa², Núria Sapena³, Roberto Gumucio², Raimon Sanmarti² and Jose A Gomez-Puerta², ¹Hospital Universitari Clinic de Barcelona, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clínic, Barcelona, Spain
Background/Purpose: Rheumatoid arthritis (RA) is frequently associated with different comorbidities. Depression and fatigue are common in RA patients with a prevalence of 17-39-%(1) and 40%(2)…
Abstract Number: 0636 • ACR Convergence 2021
Contraceptive and Pre-conception Counseling in an Academic Rheumatology Practice: A Needs Assessment to Identify Gaps in Care
Tara Skorupa¹, Guiset Carvajal², Kristin Sturm¹, Ju Young Kwag³, JoAnn Zell¹ and Kristen Demoruelle¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Colorado, Colorado, CO, ³University of Colorado, Denver, CO
Background/Purpose: Systemic autoimmune conditions affect women of childbearing age, and teratogenic medications are commonly prescribed as treatment. In this study, we surveyed rheumatology patients to…
Abstract Number: 0607 • ACR Convergence 2021
Validation Studies of Rheumatoid Arthritis Patient-Reported Outcome Measures in Diverse Populations at Risk for Inequity: A Systematic Review
Cheryl Barnabe¹, Aimee Wattiaux², Jennifer Petkovic³, Dorcas Beaton⁴, Beverley Shea³, Regina Greer-Smith⁵, Jennifer Humphreys⁶, Christie Bartels⁷, Peter Tugwell³ and Valerie Umaefulam¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Wisconsin, Madison, WI, ³University of Ottawa, Ottawa, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Healthcare Research Associates, Hazel Crest, IL, ⁶University of Manchester, Manchester, United Kingdom, ⁷University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Existing patient-reported outcome measures (PROMs) in rheumatoid arthritis (RA) may be limited in their applicability to populations that experience inequities. We conducted a systematic…
Abstract Number: 0544 • ACR Convergence 2021
Targeting CD13/aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis
Eliza Pei-Suen Tsou, M.Asif Amin, Phillip Campbell, Mikel Gurrea-Rubio, Morgan Omara, Ellen Model, Pamela Palisoc, Mustafa Ali, Sirapa Vichaikul, Jonatan Hervoso, Jeffrey Ruth, Dinesh Khanna and David Fox, University of Michigan, Ann Arbor, MI
Background/Purpose: Aminopeptidase N, also known as CD13, is a Zn2+-dependent membrane bound ectopeptidase widely expressed in mammalian cells including rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS),…
Abstract Number: 0419 • ACR Convergence 2021
Post-induction ANCA Titer Does Not Predict Mortality or Renal Outcomes: A Target Trial Emulation Study
Gregory McDermott¹, Xiaoqing Fu², Claire Cook³, John Stone⁴, Yuqing Zhang⁵ and Zachary Wallace⁶, ¹Brigham and Women's Hospital, Brookline, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, ⁶Massachusetts General Hospital, Newton, MA
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is associated with increased risk of end-stage renal disease (ESRD) and death. In most cases, circulating ANCA targeting…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].